A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)

Martin Forster; Allan Hackshaw; Tommaso De Pas; Manuel Cobo; Pilar Garrido; Yvonne Summers; Anne-Marie C. Dingemans; Michael Flynn; David Schnell; Ute von Wangenheim; Arsene-Bienvenu Loembe; Rolf Kaiser; Siow Ming Lee

doi:10.1016/j.lungcan.2018.03.007

A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)

Martin Forster, Allan Hackshaw, Tommaso De Pas, Manuel Cobo, Pilar Garrido, Yvonne Summers, Anne-Marie C. Dingemans, Michael Flynn, David Schnell, Ute von Wangenheim, Arsene-Bienvenu Loembe, Rolf Kaiser, Siow Ming Lee

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	27-33
Number of pages	7
Journal	Lung Cancer
Volume	120
DOIs	https://doi.org/10.1016/j.lungcan.2018.03.007
Publication status	Published - 1 Jun 2018

Keywords

Nintedanib
Non-small cell lung cancer
Squamous
TRIPLE ANGIOKINASE INHIBITOR
CLINICAL-PRACTICE GUIDELINES
LABEL DOSE-ESCALATION
BIBF 1120
CONTROLLED-TRIAL
CARBOPLATIN
PACLITAXEL
BEVACIZUMAB
PHARMACOKINETICS
ANGIOGENESIS

Cite this

Forster, M., Hackshaw, A., De Pas, T., Cobo, M., Garrido, P., Summers, Y., Dingemans, A-M. C., Flynn, M., Schnell, D., von Wangenheim, U., Loembe, A-B., Kaiser, R., & Lee, S. M. (2018). A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3). Lung Cancer, 120, 27-33. https://doi.org/10.1016/j.lungcan.2018.03.007

Forster, Martin ; Hackshaw, Allan ; De Pas, Tommaso ; Cobo, Manuel ; Garrido, Pilar ; Summers, Yvonne ; Dingemans, Anne-Marie C. ; Flynn, Michael ; Schnell, David ; von Wangenheim, Ute ; Loembe, Arsene-Bienvenu ; Kaiser, Rolf ; Lee, Siow Ming. / A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3). In: Lung Cancer. 2018 ; Vol. 120. pp. 27-33.

@article{259dbe45c141426da7ce06df734f1edc,

title = "A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)",

keywords = "Nintedanib, Non-small cell lung cancer, Squamous, TRIPLE ANGIOKINASE INHIBITOR, CLINICAL-PRACTICE GUIDELINES, LABEL DOSE-ESCALATION, BIBF 1120, CONTROLLED-TRIAL, CARBOPLATIN, PACLITAXEL, BEVACIZUMAB, PHARMACOKINETICS, ANGIOGENESIS",

author = "Martin Forster and Allan Hackshaw and {De Pas}, Tommaso and Manuel Cobo and Pilar Garrido and Yvonne Summers and Dingemans, {Anne-Marie C.} and Michael Flynn and David Schnell and {von Wangenheim}, Ute and Arsene-Bienvenu Loembe and Rolf Kaiser and Lee, {Siow Ming}",

year = "2018",

month = jun

day = "1",

doi = "10.1016/j.lungcan.2018.03.007",

language = "English",

volume = "120",

pages = "27--33",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

Forster, M, Hackshaw, A, De Pas, T, Cobo, M, Garrido, P, Summers, Y, Dingemans, A-MC, Flynn, M, Schnell, D, von Wangenheim, U, Loembe, A-B, Kaiser, R & Lee, SM 2018, 'A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)', Lung Cancer, vol. 120, pp. 27-33. https://doi.org/10.1016/j.lungcan.2018.03.007

A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3). / Forster, Martin; Hackshaw, Allan; De Pas, Tommaso; Cobo, Manuel; Garrido, Pilar; Summers, Yvonne; Dingemans, Anne-Marie C.; Flynn, Michael; Schnell, David; von Wangenheim, Ute; Loembe, Arsene-Bienvenu; Kaiser, Rolf; Lee, Siow Ming.

In: Lung Cancer, Vol. 120, 01.06.2018, p. 27-33.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)

AU - Forster, Martin

AU - Hackshaw, Allan

AU - De Pas, Tommaso

AU - Cobo, Manuel

AU - Garrido, Pilar

AU - Summers, Yvonne

AU - Dingemans, Anne-Marie C.

AU - Flynn, Michael

AU - Schnell, David

AU - von Wangenheim, Ute

AU - Loembe, Arsene-Bienvenu

AU - Kaiser, Rolf

AU - Lee, Siow Ming

PY - 2018/6/1

Y1 - 2018/6/1

KW - Nintedanib

KW - Non-small cell lung cancer

KW - Squamous

KW - TRIPLE ANGIOKINASE INHIBITOR

KW - CLINICAL-PRACTICE GUIDELINES

KW - LABEL DOSE-ESCALATION

KW - BIBF 1120

KW - CONTROLLED-TRIAL

KW - CARBOPLATIN

KW - PACLITAXEL

KW - BEVACIZUMAB

KW - PHARMACOKINETICS

KW - ANGIOGENESIS

U2 - 10.1016/j.lungcan.2018.03.007

DO - 10.1016/j.lungcan.2018.03.007

M3 - Article

VL - 120

SP - 27

EP - 33

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -

Access to Document

10.1016/j.lungcan.2018.03.007

http://discovery.ucl.ac.uk/10047686/1/Forster%20M%20et%20al%20LUME-Lung%203_Lung%20Cancer.pdf